This is a working overview of gastric juice protein, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-26 and is reviewed periodically as new material appears.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentadecapeptide | Fifteen amino acids; sequence matches a fragment of a gastric juice protein |
| Molecular formula | C62H98N16O22 | Corresponds to a molecular mass near 1419 Da |
| Primary origin | Fragment of human gastric juice protein BPC | First characterized in the early 1990s |
| Common synonyms | BPC 157; PL 14736; pentadecapeptide BPC 157 | Naming conventions vary across publications |
| Reported stability | Stable in gastric juice during in vitro incubation | Based on laboratory incubation, not clinical data |
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Clinical studies have repeatedly shown that even though insulin resistance is usually associated with obesity, the membrane phospholipids of the adipocytes of obese patients generally still show an increased degree of fatty acid unsaturation. This seems to point to an adaptive mechanism that allows the adipocyte to maintain its functionality, despite the increased storage demands associated with obesity and insulin resistance. A study conducted in 2013 found that, while INSIG1 and SREBF1 mRNA expression was decreased in the adipose tissue of obese mice and humans, the amount of active SREBF1 was increased in comparison with normal mice and non-obese patients. This downregulation of INSIG1 expression combined with the increase of mature SREBF1 was also correlated with the maintenance of SREBF1-target gene expression. Hence, it appears that, by downregulating INSIG1, there is a resetting of the INSIG1/SREBF1 loop, allowing for the maintenance of active SREBF1 levels. This seems to help compensate for the anti-lipogenic effects of insulin resistance and thus preserve adipocyte fat storage abilities and availability of appropriate levels of fatty acid unsaturation in face of the nutritional pressures of obesity.
=== Errors and reliability === The reliability of the results can be improved by lengthening the testing time. For example, if counting beta decays for 250 minutes is enough to give an error of ± 80 years, with 68% confidence, then doubling the counting time to 500 minutes will allow a sample with only half as much 14C to be measured with the same error term of 80 years. Radiocarbon dating is generally limited to dating samples no more than 50,000 years old, as samples older than that have insufficient 14C to be measurable. Older dates have been obtained by using special sample preparation techniques, large samples, and very long measurement times. These techniques can allow measurement of dates up to 60,000 and in some cases up to 75,000 years before the present. Radiocarbon dates are generally presented with a range of one standard deviation (usually represented by the Greek letter sigma as 1σ) on either side of the mean. However, a date range of 1σ represents only a 68% confidence level, so the true age of the object being measured may lie outside the range of dates quoted. This was demonstrated in 1970 by an experiment run by the British Museum radiocarbon laboratory, in which weekly measurements were taken on the same sample for six months. The results varied widely (though consistently with a normal distribution of errors in the measurements), and included multiple date ranges (of 1σ confidence) that did not overlap with each other.
1 On 28 July 1998, a reshuffle took place following Eric Charlton's departure from Parliament, with Agricultural MLC Murray Criddle assuming his Transport portfolio. Graham Kierath lost his Labour Relations portfolio to Cheryl Edwardes, whilst Kevin Prince and John Day traded portfolios.
Peña has stated his intention for his cabinet to be composed entirely or mostly of members of the Colorado Party. The president, vice president, and the other members of the cabinet took office on 15 August 2023.
Citicoline (INN), also known as cytidine diphosphate-choline (CDP-choline) or cytidine 5'-diphosphocholine is an intermediate in the generation of phosphatidylcholine from choline, a common biochemical process in cell membranes. Citicoline is naturally occurring in the cells of human and animal tissue, in particular the organs.
Sources: en.wikipedia.org
=== Protandim voluntary recall === In December 2012, LifeVantage issued a voluntary recall of select lots (ten lots in total comprising 247,896 bottles) of Protandim due to potential health risks arising from the possible inclusion of small metal fragments in the final product. In February 2013, the company announced that it was extending the recall to include additional lots of the product, estimating the total cost of the recall at $5.9 million.
== Mode of action == When used as a food additive, ractopamine added to feed can be distributed by the blood to the muscle tissues, where it serves as a full agonist to murine (mouse or rat) TAAR1, a receptor protein (not necessarily in humans). It is also an agonist to beta-adrenergic receptors and a dopamine releasing agent. A cascade of events will then be initiated to increase protein synthesis, which results in increased muscle fiber size. Ractopamine is known to increase the rate of weight gain, improve feed efficiency, and increase carcass leanness in finishing swine. Its use in finishing swine yields about 3 kg (6.6 lb) of additional lean pork per animal, and improves feed efficiency by 10%. In cattle on 28 January 2004 Elanco Animal Health made Optaflexx commercially available in the US. Optaflexx is a "medicated feed additive that is labeled only for use in steers or market heifers (not breeding heifers or bulls) during the last 28–42 days on feed."
Ukrainian President Volodymyr Zelenskyy claimed that air defences had shot down some thirty six Shahed drones. In occupied Crimea, the regional governor said six Ukrainian drones were shot down. In an interview with Die Welt, Vadym Skibitsky, deputy head of Ukraine's military intelligence service, said the government intends to assassinate Putin "because he coordinates and decides what happens" in the war. Yevgeny Prigozhin announced the start of the turnover of Bakhmut from his Wagner mercenaries to the Russian military and his forces' withdrawal from the city. He also said they would repatriate the bodies of an American national, whom he identified as a former special forces soldier named Nicholas Maimer, and a Turkish citizen, which they claimed to have recovered from the remains of a building blown up by Ukrainian forces, adding that the body of another Turkish national, a woman, was also found but could not be retrieved. 106 Ukrainian POWs captured in Bakhmut were repatriated to Ukraine in a prisoner exchange with Russia. The FSB announced that it had arrested two members of a Ukrainian "sabotage group" and two Russian accomplices who were plotting to bomb power lines connected to the Leningrad and Kalinin Nuclear Power Plants, adding that 36.5 kilos of explosives and about 60 detonators were recovered from them. The Russian Defence Ministry said it had scrambled Su-27 and Su-35 fighter jets to intercept two US Air Force B-1B strategic bombers near the country's airspace boundary over the Baltic Sea.
== History == The history of light therapy can be traced back to ancient Egypt and India, where therapy with natural sunlight was first used to treat leucoderma. In the 1850s, Florence Nightingale's advocacy of exposure to clean air and sunlight for health restoration also contributed to the initial development of light therapy for treatments. Later, Downes and Blunt's experiment in 1877 suggested sunlight's effect on fungal growth inhibition, which further evidenced the efficiency of light therapy . The modern use of light therapy with artificial lights started in the late 19th century. The Danish Nobel Prize winner in medicine and physiology, Niels Finsen, pioneered the use of light as a therapy for skin tuberculosis (lupus vulgaris). His creation of the light device "Finsen lamp" as a lupus vulgaris treatment marked the beginning of modern light therapy. The application of LED lights in cosmetology became more popular in the 1980s, particularly for acne recovery, due to its ability of collagen production. Since the early 2000s, the use of LED light therapy in the medical field has become more versatile, including treatment for skin conditions, chronic diseases, and the realignment of human circadian rhythm. It has now become a commonly used therapy in both the beauty and medical fields.
== History == In the late 19th century, most vacuums were created using a Sprengel pump, which had the advantage of being very simple to operate, and capable of achieving quite good vacuum given enough time. Compared to later pumps, however, the pumping speed was very slow and the vapor pressure of the liquid mercury limited the ultimate vacuum. Following his invention of the molecular pump, Wolfgang Gaede invented the diffusion pump in 1915, and originally used elemental mercury as the working fluid. After its invention, the design was quickly commercialized by Leybold. It was then improved by Irving Langmuir, and W. Crawford. C.R. Burch described the possibility of using silicone oil in 1928.
Sources: en.wikipedia.org
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.
The letters abbreviate body protection compound, the name given to the parent protein isolated from gastric juice. The number is an identifier attached to the specific fragment, not a dose or a description of a chemical property.
The sequence corresponds to a segment of an endogenous gastric protein, but the isolated fifteen-amino-acid peptide is a synthetic construct. Whether the free fragment circulates in humans at measurable levels is not clearly established in the published literature.
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.